Updated: 12/07/20

As part of the OIC emergency order, will your health plan cover, before deductible and without cost share, the cost of the 2 new CPT codes for reporting laboratory tests (87636 and 87637 effective October 6, 2020) that simultaneously detect the COVID-19 virus, influenza A/B and respiratory syncytial virus?

- 87636: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique.
- 87637: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique.

Answer to Question								
Aetna	11/12/20							
	Yes							
Amerigroup - DSNP	11/12/20							
	Yes							
CHPW – Medicare	11/23/20	This has not been added to the Medicare Fee						
Advantage		Schedule. We will add them as Medicare						
		does as we follow their guidelines						
Cigna	11/23/20	Will cover codes through January 21, 2020	https://static.cigna.com/assets/chcp/resourceLibr					
			ary/medicalResourcesList/medicalDoingBusinessW					
			ithCigna/medicalDbwcCOVID-19.html					
Coordinated Care -								
Commercial								
First Choice (TPA and PPO)	12/07/20	TPA : Yes - will accept the 2 new codes and						
		cover them without patient cost share						
		PPO Network:						
		1) Will accept the 2 new codes						
		2) Please reach out to the individual Payers						
		to confirm benefits.						
		FCH is encouraging all FCH payors to						
		waive patient responsibility for COVID-						
		19 diagnostics, including testing services,						

As part of the OIC emergency order, will your health plan cover, before deductible and without cost share, the cost of the 2 new CPT codes for reporting laboratory tests (87636 and 87637 effective October 6, 2020) that simultaneously detect the COVID-19 virus, influenza A/B and respiratory syncytial virus?

- 87636: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique.
- 87637: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique.

Answer to Question							
		performed in accordance with the					
		Families First Coronavirus Response Act					
		and the CARES Act.					
HCA Apple Health	11/10/20		https://www.hca.wa.gov/assets/billers-and-				
	Yes		providers/apple-health-covid-testing-clinical-				
			policy.pdf				
Medicaid FFS	11/10/20	See HCA Apple Health above					
	Yes						
Amerigroup	11/10/20	See HCA Apple Health above					
	Yes						
СНРЖ	11/10/20	See HCA Apple Health above					
	Yes						
Coordinated Care	11/10/20	See HCA Apple Health above					
	Yes						
Molina	11/10/20	See HCA Apple Health above					
	Yes						
UHC Community Plan	11/10/20	See HCA Apple Health above					
	Yes						
KP-NW	11/10/20						
KP-WA	Yes						
Labor & Industries	11/10/20	Not covering these two CPT codes at this					
	No	time.					
Molina - Marketplace							
Pacific Source	11/10/20						

As part of the OIC emergency order, will your health plan cover, before deductible and without cost share, the cost of the 2 new CPT codes for reporting laboratory tests (87636 and 87637 effective October 6, 2020) that simultaneously detect the COVID-19 virus, influenza A/B and respiratory syncytial virus?

- 87636: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique.
- 87637: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique.

Answer to Question					
	Yes				
Premera	11/23/20				
	Yes				
Providence	11/24/20				
	Yes				
Regence	11/10/20				
	Yes				
UHC - Commercial					